Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 5 of 15

 
 

Zoetis (NYSE:ZTS)

Consensus Rating
Buy
Rating Score
3.1
Ratings Breakdown
10 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$211.89 (26.9% Upside)

About Zoetis

Zoetis logoZoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
1/7/2025Stifel NicolausLower Price TargetBuy ➝ Buy$210.00 ➝ $180.00
12/9/2024UBS GroupInitiated CoverageNeutral$196.00
12/2/2024Leerink PartnrsUpgradeStrong-Buy
12/2/2024Leerink PartnersInitiated CoverageOutperform$215.00
10/11/2024JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$225.00 ➝ $230.00
9/18/2024Stifel NicolausBoost Price TargetBuy ➝ Buy$200.00 ➝ $210.00
8/27/2024Stifel NicolausReiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
8/14/2024Piper SandlerBoost Price TargetOverweight ➝ Overweight$195.00 ➝ $210.00
8/12/2024BTIG ResearchBoost Price TargetBuy ➝ Buy$220.00 ➝ $225.00
8/9/2024ArgusUpgradeStrong-Buy